Studies of F-ESWT in recalcitrant non-calcific rotator cuff tendinopathy
| Treatment | Ref | Design | System type | N | Dose regime | Significant benefit at 12 weeks (or other time frame as stated)? |
|---|---|---|---|---|---|---|
| F-ESWT low energy | 11 | DB-RCT | EM | 74 | 1500 shocks @ 0.12 mJ/mm2 once monthly×3 | No. Mean (SD) SPADI TG: 53.6 (20.2) to 34.7 (26.6) vs CG: 59.5 (16.1) to 39.7 (27.7) |
| 38 | DB-RCT | EM | 40 | 2000 shocks @0.11 mJ/mm2 once weekly×3 | No. Mean (SD) CMS: 42.2(13.04) to 64.39 (32.68) vs CG: 40.7 (13.29) to 66.5(37.92) | |
| F-ESWT high energy | 39 | DB-RT | EM | 40 | 6000 shocks @0.78 mJ/mm2 versus 6000@0.33 mJ/mm2 (ie, both high dose) | No. Mean (SD) CMS: TG: 46.37 (22.47) to 79.77(35.47) vs CG: 49.06 (20.52) to 67.89(32.94) |
DB-RCT, double-blind randomised controlled trial; DB-RT, double-blind randomised trial; EM, electromagnetic; F-ESWT, focused extracorporeal shockwave therapy.